Dupilumab (Dupixent) and Infection Risk
Dupilumab is associated with a reduced risk of serious infections, severe infections, and non-herpetic skin infections compared to placebo and other systemic immunosuppressants in patients with atopic dermatitis and other inflammatory conditions. 1, 2, 3
Overall Infection Profile
The FDA label and clinical trial data demonstrate that dupilumab does not increase overall infection rates. In fact, the drug shows a protective effect against multiple infection types 1:
- Serious infections: 0.87 per 100 patient-years (very low rate) 2
- Severe infections: 0.92 per 100 patient-years 2
- Overall infection rates: Similar to or lower than placebo (approximately 150-156 per 100 patient-years) 4
Specific Infection Risks - What Actually Happens
Infections That Are Reduced with Dupilumab:
Compared to cyclosporine and methotrexate, dupilumab significantly lowers risk of 3:
- Pneumonia
- Urinary tract infections
- Upper respiratory tract infections
- Sinusitis and otitis media
- Herpes zoster (shingles)
- Eczema herpeticum (risk ratio 0.31) 4
- Cellulitis and folliculitis
- Candidiasis and dermatophytosis
- Bacterial skin infections (risk ratio 0.44) 4
- Hepatitis B and C reactivation
- Septicemia, meningitis, tuberculosis (vs methotrexate) 3
The Conjunctivitis Issue - The Main Concern:
Conjunctivitis is the most common adverse event, occurring in 2-6% of patients 1:
- Most cases are mild and self-limited 5
- Managed conservatively with artificial tears 5
- Refer to ophthalmology only if severe, persistent, or refractory 5
- Does not require drug discontinuation in most cases
Helminth (Parasitic) Infections - Minor Consideration:
The FDA label notes mild helminth infections (primarily enterobiasis/pinworms) in 1.8% of patients 1:
- All cases were mild to moderate
- Resolved with standard anti-helminth treatment
- Did not require dupilumab discontinuation 1
Long-Term Safety Data - Up to 5 Years
The infection risk profile remains stable or improves with long-term use 2, 6:
- 5-year data shows no increase in overall infection risk
- Cumulative serious/severe infections decrease year-over-year 2, 6
- Infection rates at 5 years: consistent with year 1 data
- Treatment discontinuation due to infection: only 0.34 per 100 patient-years 2
Real-World Evidence Confirms Trial Data
A global cohort study of real-world use demonstrated 3:
- Decreased risk of herpetic skin infections (HR 0.59-0.65)
- Decreased risk of non-herpetic skin infections (HR 0.55-0.68)
- Decreased risk of systemic infections (HR 0.39-0.47)
- Compared to both methotrexate and cyclosporine
Clinical Bottom Line
Dupilumab does not require infection monitoring or prophylaxis 5:
- No laboratory monitoring required before or during treatment 5
- No increased risk of opportunistic infections
- Safer infection profile than traditional immunosuppressants
- The only infection-related concern is mild conjunctivitis, which is manageable
Key Pitfall to Avoid:
Do not withhold dupilumab due to infection concerns—it actually reduces infection risk compared to alternatives like cyclosporine, methotrexate, and mycophenolate. The infection profile is superior to conventional systemic immunosuppressants used for atopic dermatitis 3, 4.